Form 4: Kestra Medical Technologies Executive Granted Significant Equity Awards

Traci S. Umberger, General Counsel and Chief Administrative Officer of Kestra Medical Technologies, Ltd., was granted 29,412 restricted stock units and holds 541,000 stock options, aligning executive incentives with long-term company performance.

Summary

• Traci S. Umberger, a Director and Officer (General Counsel and Chief Administrative Officer) of Kestra Medical Technologies, Ltd. (KMTS), acquired 29,412 common shares in the form of restricted stock units (RSUs) on July 17, 2025.
• These RSUs were acquired at a price of $0.00 per share, indicating they are part of an equity compensation plan.
• The RSUs will vest in three equal annual installments of 9,804 shares each, on July 17, 2026, July 17, 2027, and July 17, 2028, contingent upon continued service.
• Following this transaction, Ms. Umberger beneficially owns 120,836 common shares directly.
• Additionally, Ms. Umberger holds 541,000 derivative securities in the form of stock options, which expire on March 6, 2035.
• Of these options, 324,600 are fully vested, while the remaining 216,400 will vest with 108,200 options vesting on March 6, 2026, and the final 108,200 vesting monthly over the subsequent year.

Sentiment

Score: 7

Explanation: The grant of equity awards to a key executive is generally positive as it aligns their interests with shareholders and incentivizes long-term performance. It reflects continued commitment from management.

Positives

• The grant of 29,412 restricted stock units (RSUs) to a key executive aligns management's interests with long-term shareholder value.
• The significant holding of 541,000 stock options, with a substantial portion still vesting, further incentivizes the executive's commitment to the company's future performance.

Future Outlook

The vesting schedules for both restricted stock units and stock options extend through July 2028 and March 2027 respectively, indicating a long-term incentive structure for the executive.

Management Comments

• Traci S. Umberger holds the titles of Director, General Counsel, and Chief Administrative Officer at Kestra Medical Technologies, Ltd.

Industry Context

This filing reflects a standard practice in the medical technology industry where executive compensation packages often include significant equity components like restricted stock units and stock options to align leadership incentives with company performance and shareholder value creation.

Stakeholder Impact

• Shareholders: The equity grant aligns the executive's interests with shareholder value creation, potentially leading to better long-term performance. However, it also represents potential future dilution upon vesting.
• Employees: This transaction highlights the company's compensation strategy, which may influence employee morale and retention, particularly for other executives and key personnel.

Next Steps

• Vesting of 9,804 restricted stock units on July 17, 2026.
• Vesting of 108,200 stock options on March 6, 2026.
• Monthly vesting of the remaining 108,200 stock options over the year following March 6, 2026.
• Vesting of 9,804 restricted stock units on July 17, 2027.
• Vesting of 9,804 restricted stock units on July 17, 2028.

Key Dates

Keywords

Kestra Medical Technologies, KMTS, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Compensation, Corporate Governance, Executive Compensation